TABLE 4.
Post treatment after imaging progression on atezolizumab plus bevacizumab therapy
| Treatment | All, n (%) (n = 41) | mALBI 1+2a, n (%) (n = 25) | mALBI 2b, n (%) (n = 16) | p‐value |
|---|---|---|---|---|
| MTAs | 19 (46.3) | 15 (60.0) | 4 (25.0) | 0.02 |
| TAE/TACE | 8 (19.5) | 3 (12.0) | 5 (31.2) | 0.26 |
| HAIC | 1 (2.4) | 1 (4.0) | 0 (0) | 1 |
| BSC | 13 (31.7) | 6 (24.0) | 7 (43.8) | 0.36 |
Abbreviations: BSC, best supportive care; HAIC, hepatic arterial infusion chemotherapy; mALBI, modified albumin–bilirubin; MTAs, multi‐targeted agents; TAE/TACE, transcatheter embolization/chemoembolization.